Pre-test (N = 35) | Post-test (N = 35) | ||
---|---|---|---|
mean (SD) | mean (SD) | p-valuea | |
HPV & cervical cancer knowledge (0–100%) | 56.30 (18.95) | 56.96 (19.33) | 0.858 |
Perceived susceptibility | |||
Cervical cancer (0–10) | 4.46 (1.70) | 3.37 (2.10) | 0.018 |
HPV infection (0–10) | 3.43 (1.46) | 3.03 (1.69) | 0.295 |
Perceived benefits of HPV vaccination | |||
HPV vaccine efficacy (0–12) | 9.26 (3.20) | 9.00 (3.64) | 0.638 |
HPV vaccine safety (0–9) | 6.14 (1.75) | 5.63 (2.17) | 0.074 |
Perceived barriers to vaccination (0–8) | 4.37 (1.59) | 3.89 (1.86) | 0.195 |
Decision self-efficacy (0–100%) | 84.71 (13.76) | 82.90 (19.12) | 0.955 |
N (%) | N (%) | p-valueb | |
Intention to obtain vaccine among those with < 3 doses (n = 7) Very likely/likely in next 12 months | 5 (71) | 4 (57) | 1.000 |
Very likely/likely in next 6 months | 5 (71) | 3 (43) | 0.617 |